alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 32.2

FIRST MARINER BANCORP  CERTIFICATION PURSUANT TO  18 U.S.C. SECTION 1350,  AS ADOPTED PURSUANT TO  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to, and for purposes only of, 18 U.S.C. § 1350, I, Paul B. Susie, Chief Financial Officer of First Mariner
Bancorp (the "Company") hereby certify that (i) the Annual Report of the Company on Form 10-K for the year ended December 31, 2010 filed with the Securities and
Exchange Commission (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii) information contained in the Report
fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: March 31, 2011

/s/ PAUL B. SUSIE Paul B. Susie Chief Financial Officer


---



QuickLinks
[No. 37951-8-I.

Division One.

June 16, 1997.]

#### The State of Washington, *Respondent,*v. Roderick Dewayne Bass, *Appellant.*

Appeal from a judgment of the Superior Court for Snohomish County, No. 95-1-00717-6, Kathryn E. Trumbull, J., entered December 26, 1995. *Dismissed*by unpublished per curiam opinion.
§ 520.292 Capromorelin. ( a ) *Specifications.* Each milliliter of solution contains: ( 1 ) 30 milligrams (mg) capromorelin; or
( 2 ) 20 mg capromorelin.
( b ) *Sponsor.* See No. 058198 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Dogs.* Use product described in paragraph (a)(1) of this section as follows: ( i ) *Amount.* Administer 3 mg/kg once daily by mouth.
( ii ) *Indications for use.* For appetite stimulation in dogs.
( iii ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) *Cats.* Use product described in paragraph (a)(2) of this section as follows: ( i ) *Amount.* Administer 2 mg/kg once daily by mouth.
( ii ) *Indications for use.* For management of weight loss in cats with chronic kidney disease.
( iii ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[81 FR 59133, Aug. 29, 2016, as amended at 85 FR 4207, Jan. 24, 2020; 86 FR 17063, Apr. 1, 2021]
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
       
<S>                                        <C>
<PERIOD-TYPE>                                    9-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               SEP-30-1997
<CASH>                                         351,111
<SECURITIES>                                         0
<RECEIVABLES>                                  264,337
<ALLOWANCES>                                  (59,101)
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                      43,929,488
<DEPRECIATION>                              22,928,947
<TOTAL-ASSETS>                              31,296,788
<CURRENT-LIABILITIES>                        1,516,057
<BONDS>                                     23,706,752
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                   6,073,479
<TOTAL-LIABILITY-AND-EQUITY>                31,296,288
<SALES>                                              0
<TOTAL-REVENUES>                            13,867,189
<CGS>                                                0
<TOTAL-COSTS>                               13,363,972
<OTHER-EXPENSES>                                90,841
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                           1,047,954
<INCOME-PRETAX>                             10,994,191
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                10,994,191
<EPS-PRIMARY>                                   125.33
<EPS-DILUTED>                                   125.33
        

</TABLE>
Office of Inspector General 

U.S. Department of Homeland Security

Washington, DC 20528

Summary of 

A Review of the Use of Alternative Screening Procedures at an Unnamed Airport 

(OIG-04-28) 

We undertook this review at the request of a Senator who referred to us a report by a Transportation 

Security Administration (TSA) screener that an airport may have been using an unauthorized 

procedure to screen checked baggage. Our review assessed whether the airport screened checked 

baggage according to applicable laws and TSA standards, and whether any alternative procedures 

used maintain security effectiveness and efficiency. 

The reviewed airport used a TSA-approved alternative screening procedure, a variation of explosive 

trace detection. TSA does not always screen checked baggage according to its standard operating 

procedures because it has insufficient equipment and human resources to adjust to high passenger 

volume, equipment unavailability, or other issues. For these situations, TSA approved several 

alternative screening procedures, which the Aviation and Transportation Security Act authorizes. 

The reviewed airport used an alternative procedure primarily because it did not have sufficient space 

and equipment to adapt to passenger volume at peak times. Airport layout improvements and the 

installation of additional equipment in 2003 decreased the airport’s use of the procedure. 

Although the alternative procedure is authorized, we have concerns about its use. Given the 

sensitivity of the equipment, it is likely that the procedure would identify explosive traces. However, 

TSA provided inadequate guidance to standardize screeners’ use of the procedure, and we 

encountered variations in use that could diminish its effectiveness. We recommended that TSA 

conduct a technical study to determine how effective the procedure is and to test procedures to 

control the quality of screening in this manner. If the alternative procedure is effective, TSA should 

develop and disseminate clearer and more specific procedures. 

Second, TSA headquarters did a poor job of specifying how the alternative procedures are to be used 

and monitoring their use. TSA headquarters had no accurate records of the reviewed airport’s use of 

alternative screening procedures throughout 2003. Use of the alternative screening procedures is one 

indicator for TSA’s resource shortfalls. If TSA monitors the procedures’ use, TSA builds a 

knowledge base for careful deployment of the resources it does have and builds a case for more 

resources if needed. Therefore, we recommended that TSA revise the policy and program for 

alternative screening procedures, including improved reporting requirements. 

Our full report is restricted “Sensitive Security Information” and is not publicly available. TSA 

responded to the report and agreed to implement our recommended corrective actions.
Editorial Note on Part 312
Editorial Note: Nomenclature changes to part 312 appear at 69 FR 13717, Mar. 24, 2004.

§ 312.21 Phases of an investigation. An IND may be submitted for one or more phases of an investigation. The clinical investigation of a previously untested drug is generally divided into three phases. Although in general the phases are conducted sequentially, they may overlap. These three phases of an investigation are a follows: ( a ) *Phase 1.* ( 1 ) Phase 1 includes the initial introduction of an investigational new drug into humans. Phase 1 studies are typically closely monitored and may be conducted in patients or normal volunteer subjects. These studies are designed to determine the metabolism and pharmacologic actions of the drug in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. During Phase 1, sufficient information about the drug's pharmacokinetics and pharmacological effects should be obtained to permit the design of well-controlled, scientifically valid, Phase 2 studies. The total number of subjects and patients included in Phase 1 studies varies with the drug, but is generally in the range of 20 to 80.
( 2 ) Phase 1 studies also include studies of drug metabolism, structure-activity relationships, and mechanism of action in humans, as well as studies in which investigational drugs are used as research tools to explore biological phenomena or disease processes.
( b ) *Phase 2.* Phase 2 includes the controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks associated with the drug. Phase 2 studies are typically well controlled, closely monitored, and conducted in a relatively small number of patients, usually involving no more than several hundred subjects.
( c ) *Phase 3.* Phase 3 studies are expanded controlled and uncontrolled trials. They are performed after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling. Phase 3 studies usually include from several hundred to several thousand subjects.
I 

118TH CONGRESS 

2D SESSION H. R. 7507 

To designate the facility of the United States Postal Service located at 

203 East 6th Street in Lexington, Nebraska, as the ‘‘Bill Barrett Post 

Office Building’’. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 29, 2024 

Mr. SMITH of Nebraska (for himself, Mr. FLOOD, and Mr. BACON) introduced 

the following bill; which was referred to the Committee on Oversight and 

Accountability 

A BILL 

To designate the facility of the United States Postal Service 

located at 203 East 6th Street in Lexington, Nebraska, 

as the ‘‘Bill Barrett Post Office Building’’. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. BILL BARRETT POST OFFICE BUILDING. 

4 (a) DESIGNATION.—The facility of the United States 

5 Postal Service located at 203 East 6th Street in Lex6 ington, Nebraska, shall be known and designated as the 

7 ‘‘Bill Barrett Post Office Building’’. 

8 (b) REFERENCES.—Any reference in a law, map, reg9 ulation, document, paper, or other record of the United 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7507 IH

1 States to the facility referred to in subsection (a) shall 

2 be deemed to be a reference to the ‘‘Bill Barrett Post Of3 fice Building’’. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
<TABLE> <S> <C>

<ARTICLE>      5
<LEGEND>
This schedule contains summary financial information extracted from
the unaudited balance sheet and statements of operations as of and
for the nine months ended October 26, 1996 and is qualified in its
entirety by reference to such financial statements as included in the
Company's quarterly report on Form 10-Q.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          FEB-01-1997
<PERIOD-END>                               OCT-26-1996
<CASH>                                       1,373,000
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                 43,557,000
<CURRENT-ASSETS>                            49,432,000
<PP&E>                                      10,958,000
<DEPRECIATION>                               4,224,000
<TOTAL-ASSETS>                             102,882,000
<CURRENT-LIABILITIES>                       32,302,000
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                 28,238,000
<COMMON>                                            14
<OTHER-SE>                                   (953,000)
<TOTAL-LIABILITY-AND-EQUITY>               102,882,000
<SALES>                                    172,891,000
<TOTAL-REVENUES>                           172,891,000
<CGS>                                      110,864,000
<TOTAL-COSTS>                              110,864,000
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                           3,604,000
<INCOME-PRETAX>                            (1,009,000)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (1,009,000)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (1,009,000)
<EPS-PRIMARY>                                   (0.82)
<EPS-DILUTED>                                   (0.82)
        

</TABLE>
<PAGE>   1
 
                                                                    EXHIBIT 23.3
 
                       REPORT OF INDEPENDENT ACCOUNTANTS
 
TO THE BOARD OF DIRECTORS AND SHAREHOLDERS OF ESPRIT TELECOM GROUP PLC
 
     In our opinion, the consolidated balance sheets and the related
consolidated statements of income, shareholders' equity/(deficit), cash flows
and comprehensive loss present fairly, in all material respects, the financial
position of Esprit Telecom Group plc and its subsidiaries (the "Company") at
September 30, 1996 and 1997 and December 31, 1998, and the results of their
operations and their cash flows for the twelve month periods ended September 30,
1996 and 1997 and the twelve month period ended December 31, 1998 in conformity
with generally accepted accounting principles in the United States. These
financial statements are the responsibility of the Company's management; our
responsibility is to express an opinion on these financial statements based on
our audits. We conducted our audits of these financial statements and additional
information related to the Valuation and Qualifying Accounts in accordance with
United States generally accepted auditing standards which require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements, assessing the accounting principles used and significant estimates
made by management, and evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for the opinion expressed
above.
 
                                        /s/ PRICEWATERHOUSECOOPERS
                                        PricewaterhouseCoopers
 
London, England
March 3, 1999
118TH CONGRESS 

2D SESSION H. R. 7180 

AN ACT 

To designate the facility of the United States Postal Service 

located at 80 1st Street in Kingsland, Arkansas, as 

the ‘‘Kingsland ‘Johnny Cash’ Post Office’’. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 
2 

•HR 7180 EH

1 SECTION 1. KINGSLAND ‘‘JOHNNY CASH’’ POST OFFICE. 

2 (a) DESIGNATION.—The facility of the United States 

3 Postal Service located at 80 1st Street in Kingsland, Ar4 kansas, shall be known and designated as the ‘‘Kingsland 

5 ‘Johnny Cash’ Post Office’’. 

6 (b) REFERENCES.—Any reference in a law, map, reg7 ulation, document, paper, or other record of the United 

8 States to the facility referred to in subsection (a) shall 

9 be deemed to be a reference to the ‘‘Kingsland ‘Johnny 

10 Cash’ Post Office’’. 

Passed the House of Representatives June 3, 2024. 

Attest: 

Clerk. 

118TH CONGRESS 

2D SESSION H. R. 7180 

AN ACT 

To designate the facility of the United States PostOffice’’. Arkansas, as the ‘‘Kingsland ‘Johnny Cash’ Post al Service located at 80 1st Street in Kingsland,
Editorial Note on Part 201
Editorial Note: Nomenclature changes to part 201 appear at 69 FR 13717, Mar. 24, 2004.

§ 201.24 Labeling for systemic antibacterial drug products. The labeling of all systemic drug products intended for human use indicated to treat a bacterial infection, except a mycobacterial infection, must bear the following statements: ( a ) At the beginning of the label, under the product name, the labeling must state: To reduce the development of drug-resistant bacteria and maintain the effectiveness of (*insert name of antibacterial drug product*) and other antibacterial drugs, (*insert name of antibacterial drug product*) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
( b ) In the “Indications and Usage” section, the labeling must state: To reduce the development of drug-resistant bacteria and maintain the effectiveness of (*insert name of antibacterial drug product*) and other antibacterial drugs, (*insert name of antibacterial drug product*) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
( c ) In the “Precautions” section, under the “General” subsection, the labeling must state: Prescribing (*insert name of antibacterial drug product*) in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
( d ) In the “Precautions” section, under the “Information for Patients” subsection, the labeling must state:
Patients should be counseled that antibacterial drugs including (*insert name of antibacterial drug product*) should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When (*insert name of antibacterial drug product*) is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by (*insert name of antibacterial drug product*) or other antibacterial drugs in the future.
[68 FR 6081, Feb. 6, 2003]
# Fourth Court of Appeals

**San Antonio, Texas**

JUDG MENT

No. 04

- 22

- 00442

- CR

EX PARTE Juan Antonio Molina VALENCIA

From the County Court

, Maverick County, Texas

Trial Court No. 30906

Honorable Susan D. Reed , Judge Presiding

BEFORE CHIEF JUSTICE MARTINEZ

, JUSTICE CHAPA , AND JUSTICE VALENZUELA

In accordance with this court’s opinion of this date, this appeal is DISMISSED.

SIGNED January 25, 2023.

_________________________________ Luz Elena D. Chapa , Justice
# RECEI'lED
Certificate of Service 

## HEARING DOCKET
I hereby certify thaton this date I have placed in the United States mail, postage pre-paid, via

## ~Nt;\\1 M 

# &.\lr-usPS, the Supplemental Answer to Interrogatories and all attachments addressed as follows: Christopher Merrill, Complainant's Counsel Attorney, Office ofthe Regional Counsel, AWP-7.3 Western-Pacific Region Federal Aviation Administration P.O. Box 92007 Los Angeles CA 90009-2007 TEL 310-725-7105 FAX 310-725-6816
I also certifythat I sentvia USPS, a copy ofthis Certificate of Service to the following recipients:
Federal Aviation Administration 800 Independence Ave, S.W. Washington D.C. 20591 Attention: Hearing Docket Clerk, AGC-430, WilburWright Building Suite 2W1000
Dennis McGlynn, respondent 659 Dorothy Way Auburn CA 95603-3862
The Honorable Richard C. Goodwin, Administrative Law Judge Office of Hearings, M-20 U.S. Departmentof Transportation1200 New Jersey Avenue, S.E. (E-11-310} Washington D.C. 20590 

# RECEIVED MAR 052n14 

## HEARING DOCKET

I also certifythat I sent a copy ofthis certificate of service via email to: Patricia Matthews Staff Assistant (Patricia.Matthews@Dot.Gov)

P.O. Box 1416 Aurora IL 60507FDMS NO. FAA 2013·0615 (Civil Penalty Action)
SERVICE LIST- BY U.S. MAIL
ORIGINAL -VIA US MAIL Christopher Merrill, Complainant's Counsel Attorney, Office ofthe Regional Counsel, AWP-7.3 Western-Pacific Region Federal Aviation Administration P.O. Box 92007 Los Angeles CA 90009-2007 TEL 31 0·725·71 05 FAX 310-725-6816 

# RECEIVED MAR 052014 

## HEARING 

## DOCKET

ONE COPY CERTIFICATE OF SERVICE ONLY-VIA US MAIL Federal Aviation Administration 800 Independence Ave, S.W. Washington, D.C. 20591 Attention : Hearing Docket Clerk , AGC-430 Wilbur Wright Building -suite 2W1000
Dennis McGlynn Respondent 659 Dorothy Way Auburn, CA 95603-3862
The Honorable Richard C. Goodwin, Administrative Law Judge Office of Hearings, M-20 U.S. Department of Transportation 1200 New Jersey Avenue, S.E. (E-11-310) Washington D.C. 20590 TEL202·366-2139 Attorney-Advisor 202·366-5121 Legal Assistant FAX 202-366-7536 ONE COPY- VIA EMAIL PATRICIA MATTHEWS STAFF ASSISTANT (202) 366 5251 (PATRICIA.MATTHEWS@DOT.GOV)
<PAGE>   1

                                                                   EXHIBIT 10.45


                      [UNION BANK OF CALIFORNIA LETTERHEAD]

                                             COMMERCIAL PORTFOLIO ADMINISTRATION
                                                 Union Bank of California
                                                 500 S. Main Street
                                                 Suite 200
                                                 Orange, CA  92686



October 9, 1998

Mr. John Hohener, CFO
Smartflex Systems, Inc.
14312 Franklin Avenue
P.O. Box 2085
Tustin, CA  92781-2085

               NOTICE OF WAIVER
               Re:  Loan Agreement
               Dated:  September 26, 1997

Dear John:

        You have requested the following waiver in reference to the Loan
Agreement ("Agreement") in the principal sum of Twenty Seven Million Two
Hundred Thousand Dollars ($27,200,000) between Union Bank of California, N.A.
("Bank") and Smartflex Systems, Inc. ("Borrower") referred to above.

        Bank hereby waives Borrower's breach of SECTION 5.5 INVESTMENTS of the
Agreement occurring prior to October 31, 1998. Any further breach of this
section is not waived.

        Except as waived hereby, the Agreement, as the same may have previously
been waived, shall remain unaltered and in full force and effect. This letter
shall not be a waiver of any existing default or breach of a covenant unless
specified herein.

        If you agree with the foregoing, please sign the enclosed
acknowledgement copy and return it on or before October 31, 1998.

UNION BANK OF CALIFORNIA, N.A.


By      //s// Robert Thomas              By      //s//  Jim Heim
        ---------------------------              ---------------------------
Title:  Vice President                   Title:  Vice President
        ---------------------------              ---------------------------

<PAGE>   2





SMARTFLEX SYSTEMS, INC. hereby agree to and
acknowledge this waiver this 28 day of Oct.,
1998


By      //s//  John Hohener              By
        ---------------------------              ---------------------------
Title:  VP/CFO                           Title
        ---------------------------              ---------------------------
San Joaquin Valley Air Pollution Control District June 25, 2013 

Appendix H: Notice of Publication 

Annual Air Monitoring Network Plan 

APPENDIX H: Notices of Publication

 
San Joaquin Valley Air Pollution Control District June 25, 2013 

Appendix H: Notice of Publication 

Annual Air Monitoring Network Plan 

This page intentionally blank